SIM0811
Stories
-
Jiangsu Simcere registers Phase II/III trial of SIM0811 in acute ischemic stroke
Planned enrollment is 1092 participants and the study is expected to start on November 30, 2026, with primary completion projected for June 30, 2029. Researchers will compare different doses of SIM0811 to a placebo in patients treated within 4.5 to 24 hours after last known well.